Skip to main content

Pharma firms to halt clinical trials at Chinese hospitals after US inquiry

Several large pharmaceutical companies have informed a US House committee that they plan to stop running clinical trials at some hospitals in China, according to STAT. The announcement comes amid growing scrutiny of international research collaborations and regulatory pressures.

This decision could disrupt drug development timelines and force companies to reconsider where they conduct trials. For senior executives in pharma and biotech, the shift signals a need to evaluate exposure to geopolitical and regulatory risks in global research planning.

Stat

Find out more here